Hepatitis Clinical Trials

Showing 721-740 of 1,007 trials

A Phase Ⅳ Clinical Trial of the Recombinant Hepatitis E Vaccine (Escherichia Coli)

NCT02417597

This phase IV clinical study was designed to evaluate the safety and immunogenicity of the recombinant Hepatitis E vaccine(Hecolin®), manufactured by Xiamen Innovax Biotech CO., LTD., in healthy volunteers aged over 65 years of age at enrollment. The study volunteers will receive the 3 doses of Hecolin® administered intramuscularly according to a 0-1-6 month schedule.

Hepatitis E

Xiamen Innovax Biotech Co., Ltd600 participantsStarted Apr 2015

Quzhou, Zhejiang, China

UNKNOWNPhase 4

Safety and Immunogenicity of Recombinant Hepatitis B Vaccines in the Neonates

NCT02764671

The purpose of this study is to further evaluate the immunogenicity and safety of 10μg/0.5ml Recombinant Hepatitis B Vaccines(Saccharomyces Cerevisiae) in the Healthy Neonates.

HepatitisHepatitis BLiver Diseases+1 more

Shenzhen Kangtai Biological Products Co., LTD5,000 participantsStarted May 2015

Maoming, Guangdong, China • Yunfu, Guangdong, China

COMPLETEDPhase 1

Study of a New MVA Vaccine for Hepatitis C Virus

NCT01296451

The study is aimed at assessing the safety of AdCh3NSmut and the new candidate vaccine MVA-NSmut when administered sequentially, or alone, to healthy volunteers and patients with hepatitis C virus infection The study also aims at assessing the cellular immune response generated by AdCh3NSmut and MVA-NSmut administered as mentioned above.

Hepatitis C Infection

ReiThera Srl55 participantsStarted Dec 2010

Oxford, Oxfordshire, United Kingdom • Headington, Oxford, United Kingdom • High Wycombe, United Kingdom

A Phase Ⅳ Clinical Trial of the Recombinant Hepatitis E Vaccine (Escherichia Coli)

Safety and Immunogenicity of Recombinant Hepatitis B Vaccines in the Neonates

Study of a New MVA Vaccine for Hepatitis C Virus

Related Searches

Rifaximin to Prevent Recurrent HCV-Related Fibrosis After Liver Transplant

Cognitive Impairments in Chronic Hepatitis C Patients and Potential Reversibility With New Agents (CICHepC)

This Trial Evaluates Safety, Pharmacokinetic Profile and Anti-viral Response of BI 207127 and BI 201335 for Patients With Chronic Hepatitis C

Pharmacokinetic and Pharmacodynamic Study of IDN-6556 in ACLF

Switch to Tenofovir Versus Continue Lamivudine/Adefovir Treatment in Lamivudine-resistance Chronic Hepatitis B Patients

The Effects of Flaxseed Supplement on Biochemical Factors and Hepatic Fibrosis in Patients With Nonalcoholic Fatty Liver Disease

An Observational Study on Long-Term Persistence of Resistant Mutations And Durability of Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Direct Acting Antiviral (DAA)- Containing Regimens

Peginterferon Plus Ribavirin Combination Therapy for Hepatitis C Six Months After Onset of Acute Infection

Japanese Phase II Study of SB-497115-GR in Hepatitis C Virus Infected Patients

Risk of Post Transfusion Hepatitis C Virus Infection

Epidemiological Study to Evaluate the Management of Patients With Chronic Hepatitis C and Previous Treatment Failure

A Study to Characterise Immune Responses Following Immunisations With "Fendrix" or "Engerix B" Hepatitis B Vaccines

Use of Direct-acting Antiviral to Treat HCV Recurrence After Liver Transplantation (ANRSCO23CUPILT) Infection

Pilot Study to Assess Efficacy and Safety of a Triple Therapy With Asunaprevir, Daclatasvir, and BMS-791325 in HCV Genotype 4-infected Patients After Failure of Pegylated Interferon-Ribavirin Regimen

Non-investigational Study to Evaluate Adenovirus Serotype 5 (Ad5) Neutralizing Antibodies (nAb) in Patients With Chronic Hepatitis B Virus (HBV) Mono-infection

EU: A Multicenter Compassionate Use Program of Daclatasvir (BMS-790052) in Combination With Sofosbuvir With or Without Ribavirin for the Treatment of Subjects With Chronic Hepatitis C

A Open-label Study to Evaluate the Relative Bioavailability of Samatasvir (IDX184) and Food Effect in Healthy Male Participants (MK-2355-006)